65 related articles for article (PubMed ID: 9267073)
21. Comparative study between occult hepatitis C virus infection and chronic hepatitis C.
Pardo M; López-Alcorocho JM; Rodríguez-Iñigo E; Castillo I; Carreño V
J Viral Hepat; 2007 Jan; 14(1):36-40. PubMed ID: 17212642
[TBL] [Abstract][Full Text] [Related]
22. Therapy of hepatitis C: patients with normal aminotransferase levels.
Marcellin P; Lévy S; Erlinger S
Hepatology; 1997 Sep; 26(3 Suppl 1):133S-136S. PubMed ID: 9305678
[TBL] [Abstract][Full Text] [Related]
23. Natural history of hepatitis C and the impact of anti-viral therapy.
Boyer N; Marcellin P
Forum (Genova); 2000; 10(1):4-18. PubMed ID: 10717254
[TBL] [Abstract][Full Text] [Related]
24. Virus-specific T-cell responses associated with hepatitis C virus (HCV) persistence in the liver after apparent recovery from HCV infection.
Quiroga JA; Llorente S; Castillo I; Rodríguez-Iñigo E; López-Alcorocho JM; Pardo M; Carreño V
J Med Virol; 2006 Sep; 78(9):1190-7. PubMed ID: 16847959
[TBL] [Abstract][Full Text] [Related]
25. Clinical significance of hepatitis C virus infection to alcoholics with cirrhosis in Korea.
Kwon SY; Ahn MS; Chang HJ
J Gastroenterol Hepatol; 2000 Nov; 15(11):1282-6. PubMed ID: 11129222
[TBL] [Abstract][Full Text] [Related]
26. Ursodiol use is possibly associated with lower incidence of hepatocellular carcinoma in hepatitis C virus-associated liver cirrhosis.
Tarao K; Fujiyama S; Ohkawa S; Miyakawa K; Tamai S; Hirokawa S; Masaki T; Tanaka K
Cancer Epidemiol Biomarkers Prev; 2005 Jan; 14(1):164-9. PubMed ID: 15668491
[TBL] [Abstract][Full Text] [Related]
27. Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection.
Ohata K; Hamasaki K; Toriyama K; Matsumoto K; Saeki A; Yanagi K; Abiru S; Nakagawa Y; Shigeno M; Miyazoe S; Ichikawa T; Ishikawa H; Nakao K; Eguchi K
Cancer; 2003 Jun; 97(12):3036-43. PubMed ID: 12784339
[TBL] [Abstract][Full Text] [Related]
28. [Characteristics of the carriers of antibodies to hepatitis C virus with normal transaminases levels in HIV infected patients].
Ramos Paesa C; Pascual Catalán A; Arazo Garcés P; Aguirre Errasti JM; Hermida Lazcano I
An Med Interna; 1998 Sep; 15(9):459-63. PubMed ID: 10079535
[TBL] [Abstract][Full Text] [Related]
29. [Serum levels of soluble interleukin-2 receptor in alcoholic patients].
Sopeña B; Fernández-Rodríguez CM; Martínez Vázquez C; Méndez MX; de la Fuente J; Freire M; Arnillas E; Outon A
An Med Interna; 1998 Apr; 15(4):189-93. PubMed ID: 9608061
[TBL] [Abstract][Full Text] [Related]
30. Coinfections with hepatitis g and/or c virus in hepatitis B-related chronic liver disease.
Pramoolsinsap C; Sirikulchayanonta V; Busakorn W; Poovorawan Y; Hirsch P; Theamboonlers A; Lerdverasirikul P
Southeast Asian J Trop Med Public Health; 1999 Dec; 30(4):741-9. PubMed ID: 10928369
[TBL] [Abstract][Full Text] [Related]
31. Increased serum soluble IL-2 receptor levels following interferon therapy in patients with chronic hepatitis C.
Sugimura T; Motomura S; Sakai H; Nawata H
Hepatogastroenterology; 1999; 46(27):1827-30. PubMed ID: 10430354
[TBL] [Abstract][Full Text] [Related]
32. [The clinical significance of the measurement of serum soluble interleukin-2 receptors in various diseases].
Sugimoto H; Hashimoto N; Suzuki S; Gejyo F
Rinsho Byori; 1996 Feb; 44(2):176-82. PubMed ID: 8851203
[TBL] [Abstract][Full Text] [Related]
33. [Serum soluble interleukin 2 receptor in patients with squamous epithelial carcinomas of the upper aerodigestive tract].
Gottschlich S; Werner JA; Lippert BM; Görögh T; Maune S; Rudert H
Laryngorhinootologie; 1995 Aug; 74(8):508-11. PubMed ID: 7575904
[TBL] [Abstract][Full Text] [Related]
34. Serum levels of soluble interleukin-2 receptor in chronic hepatitis C treated with interferon-alpha.
Morishima I; Kumada T; Nakano S; Takeda I; Sugiyama K; Osada T; Kiriyama S; Ohki H; Suga T; Ito O
Scand J Gastroenterol; 1995 Aug; 30(8):807-11. PubMed ID: 7481551
[TBL] [Abstract][Full Text] [Related]
35. Serum soluble interleukin-2 receptor levels before and during interferon treatment in patients with chronic hepatitis B virus infection.
Sawayama Y; Hayashi J; Kawakami Y; Furusyo N; Ariyama I; Kishihara Y; Ueno K; Kashiwagi S
Dig Dis Sci; 1999 Jan; 44(1):163-9. PubMed ID: 9952238
[TBL] [Abstract][Full Text] [Related]
36. In subjects with antibody to hepatitis C virus a high serum level of interleukin-2 soluble receptor suggests activity of liver disease.
Gessoni G; Valverde S; Giacomini A; Antico F; Manoni F
J Viral Hepat; 1998 Mar; 5(2):99-103. PubMed ID: 9572034
[TBL] [Abstract][Full Text] [Related]
37. Serum thioredoxin levels as an indicator of oxidative stress in patients with hepatitis C virus infection.
Sumida Y; Nakashima T; Yoh T; Nakajima Y; Ishikawa H; Mitsuyoshi H; Sakamoto Y; Okanoue T; Kashima K; Nakamura H; Yodoi J
J Hepatol; 2000 Oct; 33(4):616-22. PubMed ID: 11059866
[TBL] [Abstract][Full Text] [Related]
38. Clinical observation of serum IL-18, IL-10 and sIL-2R levels in patients with chronic hepatitis C pre- and post antiviral treatment.
Jia H; Du J; Zhu S; Ma Y; Cai H
Chin Med J (Engl); 2003 Apr; 116(4):605-8. PubMed ID: 12875732
[TBL] [Abstract][Full Text] [Related]
39. [Serum soluble CD8 and soluble interleukin-2-receptor levels during interferon therapy in chronic hepatitis C].
Maekawa H; Ishiyama N; Furuya N; Nakahara K; Saito S; Uchimura H
Rinsho Byori; 1997 Oct; 45(10):1003-7. PubMed ID: 9369080
[TBL] [Abstract][Full Text] [Related]
40. Correlation of soluble interleukin-2 receptor levels with severity of chronic hepatitis C virus liver injury and development of hepatocellular cancer.
Izzo F; Curley S; Maio P; Leonardi E; Imparato L; Giglio S; Cremona F; Castello G
Surgery; 1996 Jul; 120(1):100-5. PubMed ID: 8693411
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
